Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) EBITDA Margin (2016 - 2020)

Historic EBITDA Margin for KalVista Pharmaceuticals (KALV) over the last 7 years, with Q2 2020 value amounting to 185.25%.

  • KalVista Pharmaceuticals' EBITDA Margin rose 1001600.0% to 185.25% in Q2 2020 from the same period last year, while for Apr 2020 it was 229.09%, marking a year-over-year decrease of 949400.0%. This contributed to the annual value of 3200.86% for FY2025, which is 34550100.0% up from last year.
  • According to the latest figures from Q2 2020, KalVista Pharmaceuticals' EBITDA Margin is 185.25%, which was up 1001600.0% from 583.96% recorded in Q1 2020.
  • In the past 5 years, KalVista Pharmaceuticals' EBITDA Margin registered a high of 90.77% during Q3 2016, and its lowest value of 93257.14% during Q1 2016.
  • Moreover, its 5-year median value for EBITDA Margin was 219.62% (2019), whereas its average is 6352.04%.
  • In the last 5 years, KalVista Pharmaceuticals' EBITDA Margin tumbled by -232428600bps in 2016 and then skyrocketed by 48417100bps in 2018.
  • Over the past 5 years, KalVista Pharmaceuticals' EBITDA Margin (Quarter) stood at 1000.0% in 2016, then skyrocketed by 55bps to 446.23% in 2017, then soared by 88bps to 55.63% in 2018, then tumbled by -147bps to 137.24% in 2019, then crashed by -35bps to 185.25% in 2020.
  • Its EBITDA Margin was 185.25% in Q2 2020, compared to 583.96% in Q1 2020 and 137.24% in Q4 2019.